Efficacy of anti-TNFa in severe and refractory neuro-behcet disease

An observational study

Anne Claire Desbois, Olga Addimanda, Anne Bertrand, Alban Deroux, Laurent Perard, Raphael Depaz, Eric Hachulla, Marc Lambert, David Launay, Benjamin Subran, Felix Ackerman, Xavier Mariette, Fleur Cohen, Isabelle Marie, Carlo Salvarini, Patrice Cacoub, David Saadoun

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

To report the safety and efficacy of anti-tumor necrosis factor a (TNFα) therapy in severe and refractory neuro-Behcet disease (NBD) patients. Observational, multicenter study including 17 BD patients (70.6% of male, with a median age of 39.3 [24-60] years), with symptomatic parenchymal NBD, refractory to previous immunosuppressant and treated with anti-TNFα (infliximab 5 mg/kg [n=13] or adalimumab [n=4]). Complete remission was defined by the disappearance of all neurological symptoms and by the improvement of radiological abnormalities at 12 months. Overall improvement following anti-TNF was evidenced in 16/17 (94.1%) patients including 6 (35.3%) complete response and 10 (58.8%) partial response. The median time to achieve remission was 3 months (1-6). The median Rankin score was 2 (1-4) at the initiation of anti-TNFα versus 1 (0-4) at the time of remission (P=0.01). Corticosteroids have been stopped in 4 (23.5%) patients, and reduced by more than 50% as compared with the dosage at baseline in 10 (58.8%) patients. Side effects occurred in 23.5% of patients and required treatment discontinuation in 17% of cases. TNF blockade represents an effective therapeutic approach for patients with severe and refractory NBD, a difficult to treat population.

Original languageEnglish
Article numbere3550
JournalMedicine (United States)
Volume95
Issue number23
DOIs
Publication statusPublished - 2016

Fingerprint

Behcet Syndrome
Observational Studies
Tumor Necrosis Factor-alpha
Immunosuppressive Agents
Multicenter Studies
Adrenal Cortex Hormones
Therapeutics
Safety
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Efficacy of anti-TNFa in severe and refractory neuro-behcet disease : An observational study. / Desbois, Anne Claire; Addimanda, Olga; Bertrand, Anne; Deroux, Alban; Perard, Laurent; Depaz, Raphael; Hachulla, Eric; Lambert, Marc; Launay, David; Subran, Benjamin; Ackerman, Felix; Mariette, Xavier; Cohen, Fleur; Marie, Isabelle; Salvarini, Carlo; Cacoub, Patrice; Saadoun, David.

In: Medicine (United States), Vol. 95, No. 23, e3550, 2016.

Research output: Contribution to journalArticle

Desbois, AC, Addimanda, O, Bertrand, A, Deroux, A, Perard, L, Depaz, R, Hachulla, E, Lambert, M, Launay, D, Subran, B, Ackerman, F, Mariette, X, Cohen, F, Marie, I, Salvarini, C, Cacoub, P & Saadoun, D 2016, 'Efficacy of anti-TNFa in severe and refractory neuro-behcet disease: An observational study', Medicine (United States), vol. 95, no. 23, e3550. https://doi.org/10.1097/MD.0000000000003550
Desbois, Anne Claire ; Addimanda, Olga ; Bertrand, Anne ; Deroux, Alban ; Perard, Laurent ; Depaz, Raphael ; Hachulla, Eric ; Lambert, Marc ; Launay, David ; Subran, Benjamin ; Ackerman, Felix ; Mariette, Xavier ; Cohen, Fleur ; Marie, Isabelle ; Salvarini, Carlo ; Cacoub, Patrice ; Saadoun, David. / Efficacy of anti-TNFa in severe and refractory neuro-behcet disease : An observational study. In: Medicine (United States). 2016 ; Vol. 95, No. 23.
@article{435e8bf7e9e845208c1352c7e7bb5fa3,
title = "Efficacy of anti-TNFa in severe and refractory neuro-behcet disease: An observational study",
abstract = "To report the safety and efficacy of anti-tumor necrosis factor a (TNFα) therapy in severe and refractory neuro-Behcet disease (NBD) patients. Observational, multicenter study including 17 BD patients (70.6{\%} of male, with a median age of 39.3 [24-60] years), with symptomatic parenchymal NBD, refractory to previous immunosuppressant and treated with anti-TNFα (infliximab 5 mg/kg [n=13] or adalimumab [n=4]). Complete remission was defined by the disappearance of all neurological symptoms and by the improvement of radiological abnormalities at 12 months. Overall improvement following anti-TNF was evidenced in 16/17 (94.1{\%}) patients including 6 (35.3{\%}) complete response and 10 (58.8{\%}) partial response. The median time to achieve remission was 3 months (1-6). The median Rankin score was 2 (1-4) at the initiation of anti-TNFα versus 1 (0-4) at the time of remission (P=0.01). Corticosteroids have been stopped in 4 (23.5{\%}) patients, and reduced by more than 50{\%} as compared with the dosage at baseline in 10 (58.8{\%}) patients. Side effects occurred in 23.5{\%} of patients and required treatment discontinuation in 17{\%} of cases. TNF blockade represents an effective therapeutic approach for patients with severe and refractory NBD, a difficult to treat population.",
author = "Desbois, {Anne Claire} and Olga Addimanda and Anne Bertrand and Alban Deroux and Laurent Perard and Raphael Depaz and Eric Hachulla and Marc Lambert and David Launay and Benjamin Subran and Felix Ackerman and Xavier Mariette and Fleur Cohen and Isabelle Marie and Carlo Salvarini and Patrice Cacoub and David Saadoun",
year = "2016",
doi = "10.1097/MD.0000000000003550",
language = "English",
volume = "95",
journal = "Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "23",

}

TY - JOUR

T1 - Efficacy of anti-TNFa in severe and refractory neuro-behcet disease

T2 - An observational study

AU - Desbois, Anne Claire

AU - Addimanda, Olga

AU - Bertrand, Anne

AU - Deroux, Alban

AU - Perard, Laurent

AU - Depaz, Raphael

AU - Hachulla, Eric

AU - Lambert, Marc

AU - Launay, David

AU - Subran, Benjamin

AU - Ackerman, Felix

AU - Mariette, Xavier

AU - Cohen, Fleur

AU - Marie, Isabelle

AU - Salvarini, Carlo

AU - Cacoub, Patrice

AU - Saadoun, David

PY - 2016

Y1 - 2016

N2 - To report the safety and efficacy of anti-tumor necrosis factor a (TNFα) therapy in severe and refractory neuro-Behcet disease (NBD) patients. Observational, multicenter study including 17 BD patients (70.6% of male, with a median age of 39.3 [24-60] years), with symptomatic parenchymal NBD, refractory to previous immunosuppressant and treated with anti-TNFα (infliximab 5 mg/kg [n=13] or adalimumab [n=4]). Complete remission was defined by the disappearance of all neurological symptoms and by the improvement of radiological abnormalities at 12 months. Overall improvement following anti-TNF was evidenced in 16/17 (94.1%) patients including 6 (35.3%) complete response and 10 (58.8%) partial response. The median time to achieve remission was 3 months (1-6). The median Rankin score was 2 (1-4) at the initiation of anti-TNFα versus 1 (0-4) at the time of remission (P=0.01). Corticosteroids have been stopped in 4 (23.5%) patients, and reduced by more than 50% as compared with the dosage at baseline in 10 (58.8%) patients. Side effects occurred in 23.5% of patients and required treatment discontinuation in 17% of cases. TNF blockade represents an effective therapeutic approach for patients with severe and refractory NBD, a difficult to treat population.

AB - To report the safety and efficacy of anti-tumor necrosis factor a (TNFα) therapy in severe and refractory neuro-Behcet disease (NBD) patients. Observational, multicenter study including 17 BD patients (70.6% of male, with a median age of 39.3 [24-60] years), with symptomatic parenchymal NBD, refractory to previous immunosuppressant and treated with anti-TNFα (infliximab 5 mg/kg [n=13] or adalimumab [n=4]). Complete remission was defined by the disappearance of all neurological symptoms and by the improvement of radiological abnormalities at 12 months. Overall improvement following anti-TNF was evidenced in 16/17 (94.1%) patients including 6 (35.3%) complete response and 10 (58.8%) partial response. The median time to achieve remission was 3 months (1-6). The median Rankin score was 2 (1-4) at the initiation of anti-TNFα versus 1 (0-4) at the time of remission (P=0.01). Corticosteroids have been stopped in 4 (23.5%) patients, and reduced by more than 50% as compared with the dosage at baseline in 10 (58.8%) patients. Side effects occurred in 23.5% of patients and required treatment discontinuation in 17% of cases. TNF blockade represents an effective therapeutic approach for patients with severe and refractory NBD, a difficult to treat population.

UR - http://www.scopus.com/inward/record.url?scp=84975510364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975510364&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000003550

DO - 10.1097/MD.0000000000003550

M3 - Article

VL - 95

JO - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

JF - Medicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries

SN - 0025-7974

IS - 23

M1 - e3550

ER -